


Docket No. 283523US0PCT



MAIL STOP PCT

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Gian L ARALDI, et al.

SERIAL NO: 10/564,974

GAU:

FILED: January 18, 2006

EXAMINER:

FOR: HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number


22850


Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Surinder Sachar
Registration No. 34,423

Richard L. Treanor

Registration No. 36,379

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 283523US0PCT		SERIAL NO. 10/564,974	
LIST OF REFERENCES CITED BY APPLICANT 				APPLICANT Gian L ARALDI, et al.			
				FILING DATE January 18, 2006		GROUP	
				U.S. PATENT DOCUMENTS			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
AA	6 235 780	05/22/01	OHUCHIDA et al.				
AB	5 281 590	01/25/94	HUSA et al.				
AC	2001 0056060	12/27/01	CAMERON et al.				
AD	2002 0004495	01/10/02	HARADA et al.				
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO			
	AE 01 46140	06/28/01	WO			NO	
	AF 1 114 816	07/11/01	EP			NO	
	AG 99 33794	07/08/99	WO			NO	
	AH 02 42268	05/30/02	WO			NO	
	AI 99 02164	01/21/99	WO			NO	
	AJ 02 24647	03/28/02	WO (with English abstract)			NO	
	AK 00 03980	01/27/00	WO (with English abstract)			NO	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AL	ABRAMOVITZ et al. "The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs", Biochimica et Biophysica Acta, vol. 1483, pages 285-293 2000					
	AM	BENOIT et al. "Latest discoveries in prostaglandin receptor modulators", Expert Opin. Ther. Patents, vol. 12, no. 8, pages 1225-1235 2002					
	AN	CHOUNG et al. "Role of EP2 Receptors and cAMP in Prostaglandin E2 Regulated Expression of Type I Collagen alpha1, Lysyl Oxidase, and Cyclooxygenase-1 Genes in Human Embryo Lung Fibroblasts", Journal of Cellular Biochemistry, vol. 71, pages 254-263 1998					
	AO	COLEMAN et al. "Prostanoids and their Receptors", In Comprehensive Medicinal Chemistry, The rational Design, Mechanistic Study and Therapeutic Application of Chemical Compounds, vol. 3, pages 643-714 1989					
	AP	COLEMAN et al. "VIII. International Union of Pharmacology Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and Their Subtypes", Pharmacological Reviews, vol. 46, no. 2, pages 205-229 1994					
	AQ	FLEISCH et al. "LY171883, 1-<2-Hydroxy-3-Propyl-4-<4-(1H-Tetrazol-5-yl) Butoxy>Phenyl>Ethanone, an Orally Active Leukotriene D4 Antagonist", Journal of Pharmacology and Experimental Therapeutics, vol. 233, no. 1, pages 148-157 1985					
	AR	FORMICA et al. "Comparative Assessment of Bone Mineral Measurements Using Dual X-ray Absorptiometry and Peripheral Quantitative Computed Tomography", Osteoporos Int, vol. 8, pages 460-467 1998					
	AS	HYMAN et al. "Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C", Journal of Viral Hepatitis, vol. 6, pages 329-336 1999					
	AT	MELTZER et al. "Substituted 3-Phenyltropane Analogs of Cocaine: Synthesis, Inhibition of Binding at Cocaine Recognition Sites, and Positron Emission Tomography Imaging", J. Med. Chem., vol. 36, pages 855-862 1993					
	AU	MIYAURA. "Role of EP4 receptor in bone resorption induced by PGE", Folia Pharmacol. Jpn., vol. 117, pages 293-297 2001					
	AV	DE MICO et al. J. Org. Chem., vol. 62, pages 6974-6977 1997				<input checked="" type="checkbox"/> Additional References sheet(s) attached	
Examiner				Date Considered			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 283523US0PCT		SERIAL NO. 10/564,974	
 LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Gian L ARALDI, et al.			
				FILING DATE January 18, 2006		GROUP	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	LEVI et al. "Regulation of Prostanoid synthesis in microglial cells and effects of prostaglandin E2 on microglial functions", Biochemie, vol. 80, pages 899-904 1998					
	AX	GAO et al. "Catalytic Asymmetric Epoxidation and Kinetic Resolution: Modified Procedures Including in Situ Derivatization", J. Am. Chem. Soc., vol. 109, pages 5765-5780 1987					
	AY	KATSUKI et al. "Synthesis of Saccharides and Related Polyhydroxylated Natural Products. 2. Simple Deoxyalditols", J. Org. Chem., vol. 47, pages 1378-1380 1982					
	AZ	TAKAYAMA et al. "Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages through the EP4 Receptor", Journal of Biological Chemistry, vol. 277, no. 46, pages 44147-44154 2002					
	AAA	TSUGENO et al. "Vertebral Fracture and Cortical Bone Changes in Corticosteroid-Induced Osteoporosis", Osteoporos Int, vol. 13, pages 650-656 2002					
	AAB	USHIKUBI et al. "Roles of Prostanoids Revealed From Studies Using Mice Lacking Specific Prostanoid Receptors", Jpn. J. Pharmacol., vol. 83, pages 279-285 2000					
	AAC						
	AAD						
	AAE						
	AAF						
	AAG						
	AAH						
	AAI						
	AAJ						
	AAK						
	AAL						
	AAM						
Examiner						Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

U.S. PCT Application Serial No: 10/564,974

Filed: January 18, 2006

Gian L ARALDI, et al.

Docket No. 283523US0PCT

STATEMENT OF RELEVANCY

- 1) References AA, AB, AE have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References have been cited in the corresponding Search Report. A copy of these references is being submitted herewith.
- 3) References AC, AD, AF-AAB are discussed in the specification. A copy of these references is being submitted herewith.
- 4) References are additional prior art known to Applicant. A copy of these references is being submitted herewith.